Details checkedStrong evidenceCheckedtrial

CIL001 (Paliroden) by Cilcare

Also known as: CIL001, Paliroden, RESPLAND

Cilcare SAS

Primary source

Company

Cilcare SAS

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 1/2

Status

Active

Target Gene

—

Route / Mode

Transtympanic injection

Confidence

92%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-06-08

Geography

United States, Europe; exact trial-country availability pending registry updates

Population

adult, diabetes, cochlear-synaptopathy, hidden-hearing-loss

Trial IDs

Mechanism

Neurotrophic small molecule delivered transtympanically to treat cochlear synaptopathy and speech-in-noise difficulty associated with auditory nerve synapse dysfunction.

Indications

Hearing Loss Sensorineural Hearing Loss Hidden Hearing Loss Cochlear Synaptopathy

Notes

Verified active Cilcare clinical program. ClinicalTrials.gov identifies RESPLAND as a Phase 1B/2A study of single transtympanic CIL001/paliroden for cochlear synaptopathy in people with type 2 diabetes and speech-in-noise difficulty.

Evidence & Sources

3 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, stage, status, route, indications, populationTags...

IDs: NCT07472907, RESPLAND, CIL001, Paliroden

Open

company

Supports: company, modality, mechanism, indications, notes

IDs: CIL001

Open

company

Supports: stage, status, indications, notes